Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel/Carboplatin +/- Herceptin Hylecta or Phesgo in HER2+ Endometrial Cancer
NCT05256225Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2022
- Primary completion
- Oct 2027
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of trastuzumab and hyaluronidase-oysk and pertuzumab + trastuzumab + hyaluronidase-zzxf in endometrial cancer (EC) (3 arms), sponsored by National Cancer Institute. Primary endpoints: Progression free survival up to 5 years, Overall survival up to 5 years and 1 more. Started Nov 2022; status: active, not recruiting.
02
Drugs
trastuzumab and hyaluronidase-oyskpertuzumab + trastuzumab + hyaluronidase-zzxf
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT05256225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05256225.